2nd Annual Pharma Pricing & Market Access Innovation Summit

Key facts

Date: 12 — 13 November, 2026

Place: Vienna

Conference Overview

Building on the success of the 1st Pharma Pricing & Market Access Innovation Summit gathering in Madrid, the 2nd Annual Pharma Pricing & Market Access Innovation Summit returns as a key meeting point for leaders shaping the future of global market access, pricing strategy, and reimbursement.

Taking place in November 2026, the summit brings together senior executives in pricing, HEOR, market access, payer engagement, and regulatory affairs to address the evolving pressures of affordability, value demonstration, and access innovation across international markets. With an expanded speaker lineup and a broader global audience, this next edition offers a deeper exploration of the forces transforming pricing and access today.

Discussions will focus on the practical realities of delivering sustainable pricing models, aligning with shifting HTA expectations, advancing patient-centric access pathways, and harnessing digital technologies that are redefining evidence generation and reimbursement processes. Through case studies, panel debates, and collaborative working sessions, attendees will gain concrete strategies to navigate increasing complexity while supporting both innovation and equitable access.

As the industry faces rapid policy change, rising scrutiny, and new opportunities for cross-stakeholder collaboration, the summit provides a timely platform for open dialogue, shared learning, and strategic alignment.

Join us as we explore how the sector can move toward a more transparent, value-driven, and sustainable market access future.

Key topics

Understand how global pricing reforms are reshaping launch sequencing and lifecycle strategy across the US, EU, Middle East, and emerging markets.
Navigate the growing divergence between HTA systems and payer expectations – and identify where convergence is realistically possible.
Assess the commercial implications of IRA, reference pricing pressure, and geopolitical shifts on global price corridors and portfolio planning.
Design pricing and market access strategies for rare diseases and high-value innovation in increasingly restrictive funding environments.
Evaluate the evolving balance between reimbursed and self-pay markets, and understand when alternative funding mechanisms become viable.
Integrate patient engagement into access strategy in a way that supports evidence generation, value communication, and reimbursement success.
Leverage public–private partnerships and cross-sector collaboration to expand access without eroding long-term price integrity.
Anticipate the next wave of HTA transformation, including joint clinical assessments and evolving evidence requirements.
Strengthen cross-functional alignment between global, regional, and affiliate teams to avoid internal value leakage.
Benchmark your pricing governance, negotiation tactics, and payer engagement models against peers facing similar pressures.